81 related articles for article (PubMed ID: 8275036)
1. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
[TBL] [Abstract][Full Text] [Related]
2. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
Stockschläder M; Kalhs P; Peters S; Zeller W; Krüger W; Kabisch H; Lechner K; Zander A
Bone Marrow Transplant; 1993 Oct; 12(4):357-62. PubMed ID: 8275035
[TBL] [Abstract][Full Text] [Related]
3. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
4. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
5. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.
van der Jagt RH; Pari G; McDiarmid SA; Boisvert DM; Huebsch LB
Bone Marrow Transplant; 1994 Feb; 13(2):203-7. PubMed ID: 8205090
[TBL] [Abstract][Full Text] [Related]
6. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281
[TBL] [Abstract][Full Text] [Related]
7. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation of busulfan with pentoxifylline and ciprofloxacin in patients with breast cancer undergoing autologous transplants.
Bensinger WI; Buckner CD; Lilleby K; Holmberg L; Storb R; Slattery JT
Oncology; 2004; 67(5-6):368-75. PubMed ID: 15713992
[TBL] [Abstract][Full Text] [Related]
9. [Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation].
López J; Cancelas JA; Valiño JM; García-Laraña J; Sastre JL; Pérez-Oteyza J; Cerveró C; García-Avello A; Cabezudo E; Arranz MI
Med Clin (Barc); 1994 Apr; 102(13):485-8. PubMed ID: 8208006
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
11. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.
Ljungman P; Hassan M; Békássy AN; Ringdén O; Oberg G
Bone Marrow Transplant; 1997 Dec; 20(11):909-13. PubMed ID: 9422468
[TBL] [Abstract][Full Text] [Related]
12. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
13. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
15. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
16. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
17. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.
Reece DE; Barnett MJ; Connors JM; Klingemann HG; O'Reilly SE; Shepherd JD; Sutherland HJ; Phillips GL
Bone Marrow Transplant; 1993 Feb; 11(2):139-46. PubMed ID: 8435663
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation.
Bianco JA; Appelbaum FR; Nemunaitis J; Almgren J; Andrews F; Kettner P; Shields A; Singer JW
Blood; 1991 Sep; 78(5):1205-11. PubMed ID: 1878587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
